

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u>  (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u>  (Street) <u>CAMBRIDGE MA 02142</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TCR2 THERAPEUTICS INC. [ TCRR ]</u>  3. Date of Earliest Transaction (Month/Day/Year) <u>02/19/2019</u>  4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)  6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person
---	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/19/2019		C		79,644	A	(1)	79,644	I	See Footnote(2)
Common Stock	02/19/2019		C		52,469	A	(1)	52,469	I	See Footnote(3)
Common Stock	02/19/2019		C		146,447	A	(1)	146,447	I	See Footnote(4)
Common Stock	02/19/2019		C		2,195,681	A	(1)	2,195,681	I	See Footnote(5)
Common Stock	02/19/2019		C		351,155	A	(1)	351,155	I	See Footnote(6)
Common Stock	02/19/2019		C		2,421,775	A	(1)	2,421,775	I	See Footnote(7)
Common Stock	02/19/2019		C		9,291	A	(8)	88,935	I	See Footnote(2)
Common Stock	02/19/2019		C		5,247	A	(8)	57,716	I	See Footnote(3)
Common Stock	02/19/2019		C		17,085	A	(8)	163,532	I	See Footnote(4)
Common Stock	02/19/2019		C		256,163	A	(8)	2,451,844	I	See Footnote(5)
Common Stock	02/19/2019		C		35,115	A	(8)	386,270	I	See Footnote(6)
Common Stock	02/19/2019		C		282,540	A	(8)	2,704,315	I	See Footnote(7)
Common Stock	02/19/2019		P		1,373,333	A	\$15	1,569,235	I	See Footnote(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	02/19/2019		C			493,306	(1)	(1)	Common Stock	79,644	(1)	0	I	See Footnote(2)
Series A Preferred Stock	(1)	02/19/2019		C			325,002	(1)	(1)	Common Stock	52,469	(1)	0	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	02/19/2019		C			907,073	(1)	(1)	Common Stock	146,447	(1)	0	I	See Footnote <sup>(4)</sup>
Series A Preferred Stock	(1)	02/19/2019		C			13,599,621	(1)	(1)	Common Stock	2,195,681	(1)	0	I	See Footnote <sup>(5)</sup>
Series A Preferred Stock	(1)	02/19/2019		C			2,174,998	(1)	(1)	Common Stock	351,155	(1)	0	I	See Footnote <sup>(6)</sup>
Series A Preferred Stock	(1)	02/19/2019		C			15,000,000	(1)	(1)	Common Stock	2,421,775	(1)	0	I	See Footnote <sup>(7)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			57,552	(8)	(8)	Common Stock	9,291	(8)	0	I	See Footnote <sup>(2)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			32,500	(8)	(8)	Common Stock	5,247	(8)	0	I	See Footnote <sup>(3)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			105,825	(8)	(8)	Common Stock	17,085	(8)	0	I	See Footnote <sup>(4)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			1,586,623	(8)	(8)	Common Stock	256,163	(8)	0	I	See Footnote <sup>(5)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			217,500	(8)	(8)	Common Stock	35,115	(8)	0	I	See Footnote <sup>(6)</sup>
Series B Preferred Stock	(8)	02/19/2019		C			1,750,000	(8)	(8)	Common Stock	282,540	(8)	0	I	See Footnote <sup>(7)</sup>

**Explanation of Responses:**

- Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value \$0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
- The reported securities are owned directly by MPM Asset Management Investors BV2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM Asset Management Investors SunStates Fund LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures 2014, L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014, L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM SunStates Fund, L.P. MPM SunStates Fund GP LLC is the general partner of MPM SunStates Fund, L.P. MPM SunStates GP Managing Member LLC is the managing member of MPM SunStates Fund GP LLC. The Reporting Person is a member of MPM SunStates Fund GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are held directly by UBS Oncology Impact Fund, L.P. The general partner of UBS Oncology Impact Fund, L.P. is Oncology Impact Fund (Cayman) Management L.P. The general partner of Oncology Impact Fund (Cayman) Management L.P. is MPM Oncology Impact Management LP. The general partner of MPM Oncology Impact Management LP is MPM Oncology Impact Management GP LLC. The Reporting Person is the managing director of MPM Oncology Impact Management GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
- The reported securities are owned directly by MPM Asset Management LLC. The Reporting Person is a member of MPM Asset Management LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

**Remarks:**

/s/ Ansbert Gadicke

\*\* Signature of Reporting Person

02/21/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**